Improved uptake and therapeutic intervention of curcumin via designing binary lipid nanoparticulate formulation for oral delivery in inflammatory bowel disorder

References

• De Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13–27.
   PubMed Web of Science ®Google Scholar
• Abegunde AT, Muhammad BH, Bhatti O, et al. Environmental risk factors for inflammatory bowel diseases: evidence based literature review. World J Gastroenterol. 2016;22:6296–6317.
   PubMed Web of Science ®Google Scholar
• Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterol. 2008;134:929–936.
   PubMed Web of Science ®Google Scholar
• Schirbel A, Fiocchi C. Inflammatory bowel disease: established and evolving considerations on its etiopathogenesis and therapy. J Dig Dis. 2010;11:266–276.
   PubMed Web of Science ®Google Scholar
• Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther. 2011;5:185–210.
   PubMed Web of Science ®Google Scholar
• Murthy SK, James PD, Antonova L, et al. High end of life health care costs and hospitalization burden in inflammatory bowel disease patients: a population-based study. PLoS One. 2017;12:e0177211.
   PubMed Web of Science ®Google Scholar
• Larussa T, Imeneo M, Luzza F. Potential role of nutraceutical compounds in inflammatory bowel disease. World J Gastroenterol. 2017;23:2483–2492.
   PubMed Web of Science ®Google Scholar
• Kinney SRM, Carlson L, Ser-Dolansky J, et al. Curcumin ingestion inhibits mastocytosis and suppresses intestinal anaphylaxis in a murine model of food allergy. PLoS One. 2015;10:e0132467.
   PubMed Web of Science ®Google Scholar
• Larasati1 YA, Yoneda-Kato N, Nakamae I, et al. Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth. Sci Rep. 2018;8:2039.
   PubMed Web of Science ®Google Scholar
• Arafa HM, Hemeida RA, El-Bahrawy A, et al. Prophylactic role of curcumin in dextran sulfate sodium (DSS)-induced ulcerative colitis murine model. Food Chem Toxicol. 2009;47:1311–1317.
   PubMed Web of Science ®Google Scholar
• Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol. 2007;595:453–470.
   PubMed Web of Science ®Google Scholar
• Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004;10:6847–6854.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wu Q, Zhang Z, et al. Preparation of curcumin-loaded liposomes and evaluation of their skin permeation and pharmacodynamics. Molecules. 2012;17:5972–5987.
   PubMed Web of Science ®Google Scholar
• Cheng C, Peng S, Li Z, et al. Improved bioavailability of curcumin in liposomes prepared using a pH-driven, organic solvent-free, easily scalable process. RSC Adv. 2017;7:25978–25986.
   Web of Science ®Google Scholar
• Yadav VR, Suresh S, Devi K, et al. Effect of cyclodextrin complexation of curcumin on its solubility and antiangiogenic and anti-inflammatory activity in rat colitis model. AAPS PharmSciTech. 2009;10:752–762.
   PubMed Web of Science ®Google Scholar
• Dhumal DM, Kothari PR, Kalhapure RS, et al. Self-microemulsifying drug delivery system of curcumin with enhanced solubility and bioavailability using a new semi-synthetic bicephalous heterolipid: in vitro and in vivo evaluation. RSC Adv. 2015;5:90295–90306.
   Web of Science ®Google Scholar
• Köllner S, Nardin I, Markt R, et al. Self-emulsifying drug delivery systems: design of a novel vaginal delivery system for curcumin. Eur J Pharm Biopharm. 2017;115:268–275.
   PubMed Web of Science ®Google Scholar
• Chaurasia S, Chaubey P, Patel RR, et al. Curcumin-polymeric nanoparticles against colon-26 tumor-bearing mice: cytotoxicity, pharmacokinetic and anticancer efficacy studies. Drug Dev Ind Pharm. 2016;42:694–700.
   PubMed Web of Science ®Google Scholar
• De Almeida M, da Rocha BA, Francisco CRL, et al. Evaluation of the in vivo acute antiinflammatory response of curcumin-loaded nanoparticles. Food Funct. 2018;9:440–449.
   PubMed Web of Science ®Google Scholar
• Ji H, Tang J, Li M, et al. Curcumin-loaded solid lipid nanoparticles with Brij78 and TPGS improved in vivo oral bioavailability and in situ intestinal absorption of curcumin. Drug Deliv. 2016;23:459–470.
   PubMed Web of Science ®Google Scholar
• Shrotriya S, Ranpise N, Satpute P, et al. Skin targeting of curcumin solid lipid nanoparticles-engrossed topical gel for the treatment of pigmentation and irritant contact dermatitis. Artif Cells Nanomed Biotechnol. 2017;46:1471–1482.
   PubMed Web of Science ®Google Scholar
• Shukla P, Dwivedi P, Gupta PK, et al. Optimization of novel tocopheryl acetate nanoemulsions for parenteral delivery of curcumin for therapeutic intervention of sepsis. Expert Opin Drug Deliv. 2014;11:1697–1712.
   PubMed Web of Science ®Google Scholar
• Rachmawati H, Budiputra DK, Mauludin R. Curcumin nanoemulsion for transdermal application: formulation and evaluation. Drug Dev Ind Pharm. 2015;41:560–566.
   PubMed Web of Science ®Google Scholar
• Collnot EM, Ali H, Lehr CM. Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J Control Release. 2012;161:235–246.
   PubMed Web of Science ®Google Scholar
• Beloqui A, Coco R, Alhouayek M, et al. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis. Int J Pharm. 2013;454:775–783.
   PubMed Web of Science ®Google Scholar
• Cacciatore l, Ciulla M, Fornasari E, et al. Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases. Expert Opin Drug Deliv. 2016;13:1121–1131.
   PubMed Web of Science ®Google Scholar
• Dianzani C, Foglietta F, Ferrara B, et al. Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: effects in an in vivo model. World J Gastroenterol. 2017;23:4200–4210.
   PubMed Web of Science ®Google Scholar
• Sharma M, Gupta N, Gupta S. Implications of designing clarithromycin loaded solid lipid nanoparticles on their pharmacokinetics, antibacterial activity and safety. RSC Adv. 2016;6:76621–76631.
   Web of Science ®Google Scholar
• Subramanian AP, Jaganathan SK, Manikandan A, et al. Recent trends in nano-based drug delivery systems for efficient delivery of phytochemicals in chemotherapy. RSC Adv. 2016;6:48294–48314.
   Web of Science ®Google Scholar
• Serpe L, Canaparo R, Daperno M, et al. Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model. Eur J Pharm Sci. 2010;39:428–436.
   PubMed Web of Science ®Google Scholar
• Yuan H, Chen CY, Chai GH, et al. Improved transport and absorption through gastrointestinal tract by pegylated solid lipid nanoparticles. Mol Pharmaceutics. 2013;10:1865–1873.
   PubMed Web of Science ®Google Scholar
• Iwanaga T, Hoshi O, Han H, et al. Morphological analysis of acute ulcerative colitis experimentally induced by dextran sulfate sodium in the guinea pig: some possible mechanisms of cecal ulceration. J Gastroenterol. 1994;29:430–438.
   PubMed Web of Science ®Google Scholar
• Shi C, Liang Y, Yang J, et al. MicroRNA-21 knockout improve the survival rate in DSS induced fatal colitis through protecting against inflammation and tissue injury. PLoS One. 2013;8:e66814.
   PubMed Web of Science ®Google Scholar
• Sharma M, Sharma R. Implications of designing bromelain loaded enteric nanoformulation on its stability and anti-inflammatory potential upon oral administration. RSC Adv. 2018;8:2541–2551.
   PubMed Web of Science ®Google Scholar
• Fagan JM, Sleczka BG, Sohar I. Quantitation of oxidative damage to tissue proteins. Int J Biochem Cell Biol. 1999;31:751–757.
   PubMed Web of Science ®Google Scholar
• Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS Pharm Sci Tech. 2011;12:62–74.
   PubMed Web of Science ®Google Scholar
• Singh B, Vuddanda PR, Kumar MRV, et al. Cefuroxime axetil loaded solid lipid nanoparticles for enhanced activity against S. aureus biofilm. Colloids Surf B. 2014;12:92–98.
   Web of Science ®Google Scholar
• Hong SS, Kim SH, Lim SJ. Effect of triglycerides on hydrophobic drug loading capacity of saturated phosphatidylcholine based liposomes. Int J Pharm. 2015;483:142–150.
   PubMed Web of Science ®Google Scholar
• Jenning V, Thünemann AF, Gohla SH. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm. 2000;199:167–177.
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mäder K. Solid lipid nanoparticles production, characterization and application. Adv Drug Deliv Rev. 2001;49:165–196.
   Web of Science ®Google Scholar
• Ghosh I, Bose S, Vippagunta R, et al. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm. 2011;409:260–268.
   PubMed Web of Science ®Google Scholar
• Sharma M, Sharma V, Panda AK, et al. Development of enteric submicron particle formulation of papain for oral delivery. Int J Nanomedicine. 2011;6:2097–2111.
   PubMed Web of Science ®Google Scholar
• Rawat MK, Jain A, Mishra A, et al. Effect of lipid matrix on repaglinide-loaded solid lipid nanoparticles for oral delivery. Ther Deliv. 2010;1:63–73.
   PubMedGoogle Scholar
• Dandekar PP, Jain R, Patil S, et al. Curcumin-loaded hydrogel nanoparticles: application in anti-malarial therapy and toxicological evaluation. J Pharm Sci. 2010;99:4992–5010.
   PubMed Web of Science ®Google Scholar
• Zhang D, Tan T, Gao L. Preparation of oridonin-loaded solid lipid nanoparticles and studies on them in vitro and in vivo. Nanotechnol. 2006;17:5821–5828.
   Web of Science ®Google Scholar
• Xiang Q, Wang M, Chen F, et al. Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch Pharm Res. 2007;30:519–525.
   PubMed Web of Science ®Google Scholar
• Gugulothu D, Kulkarni A, Patravale V, et al. pH-sensitive nanoparticles of curcumin-celecoxib combination: evaluating drug synergy in ulcerative colitis model. J Pharm Sci. 2014;103:687–696.
   PubMed Web of Science ®Google Scholar
• Schmidt C, Lautenschlaeger C, Collnot EM, et al. Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients. J Control Release. 2013;165:139–145.
   PubMed Web of Science ®Google Scholar
• Holma R, Salmenpera P, Riutta A, et al. Acute effects of the cys-leukotriene-1 receptor antagonist, montelukast, on experimental colitis in rats. Eur J Pharmacol. 2001;429:309–318.
   PubMed Web of Science ®Google Scholar
• Wang Z, Li S, Cao Y, et al. Oxidative stress and carbonyl lesions in ulcerative colitis and associated colorectal cancer. Oxid Med Cell Longev. 2016;2016:1.
   Web of Science ®Google Scholar